Myogenic progenitor cells derived from human induced pluripotent stem cell are immune-tolerated in humanized mice

Basma Benabdallah1 | Cynthia Désaulniers-Langevin1 | Marie-Lyn Goyer1 | Chloé Colas1 | Chantale Maltais2 | Yuanyi Li1 | Jean V. Guimond3 | Jacques P. Tremblay2 | Elie Haddad1,4 | Christian Beauséjour1,5

1Centre de Recherche du CHU Ste-Justine, Montréal, Québec, Canada
2Centre de Recherche du CHUQ, Université Laval, Québec, Québec, Canada
3CIUSSS du Centre-Sud-de-l’Île-de-Montréal, Montreal, Québec, Canada
4Département de Pédiatrie, Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada
5Département de Pharmacologie et Physiologie, Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada

Correspondence
Christian Beauséjour, PhD, CHU Ste-Justine, 3175 Côte Sainte-Catherine, Montréal, QC H3T 1C5, Canada.
Email: c.beausejour@umontreal.ca

Funding information
la Fondation Charles Bruneau; le réseau ThéCell from the Fonds de la recherche du Québec - Santé (FRQS); Canadian Institute of Health Research, Grant/Award Number: #MOP-126096

Abstract
It is still unclear if immune responses will compromise the large-scale utilization of human induced pluripotent stem cells (hiPSCs)-derived cell therapies. To answer this question, we used humanized mouse models generated by the adoptive transfer of peripheral blood mononuclear cells or the cotransplantation of hematopoietic stem cells and human thymic tissue. Using these mice, we evaluated the engraftment in skeletal muscle of myoblasts derived either directly from a muscle biopsy or differentiated from hiPSCs or fibroblasts. Our results showed that while allogeneic grafts were mostly rejected and highly infiltrated with human T cells, engraftment of autologous cells was tolerated. We also observed that hiPSC-derived myogenic progenitor cells (MPCs) are not targeted by autologous T cells and natural killer cells in vitro. These findings suggest that the reprogramming and differentiation procedures we used are not immunogenic and that hiPSC-derived MPCs will be tolerated in the presence of a competent human immune system.

KEYWORDS
human induced pluripotent stem cells, humanized mice, myogenic progenitor cells

1 | INTRODUCTION

The controversial possibility that human induced pluripotent stem cell (hiPSC)-derived cells arouse an autologous immune response could compromise their use in clinic. Indeed, Zhao and colleagues were the first to observe that mouse iPSCs, but not ESCs, are immunogenic when injected in syngeneic recipients.1,2 Subsequently, numerous other studies have shown that mouse iPSC-derived cells can be weakly immunogenic in syngeneic recipients and lead to the development of mechanisms similar to self-tolerance.3-7 However, the complexity of generating humanized mouse models has limited to number of studies evaluating the immunogenicity of human iPSC-derived cells.

Using humanized BLT mice (Hu-BLT) generated from the cotransplantation of hematopoietic stem cells and human thymic tissue, the study by Zhao et al showed that autologous hiPSC-derived cells can be immunogenic.8 They showed that hiPSC-derived smooth muscle cells are immunogenic but that retinal pigment epithelial cells are not despite being derived from the same donor.8 Yet, the extent to which engrafted autologous compared to allogeneic hiPSC-derived cells were tolerated was not evaluated in their study. Indeed,
immunogenicity of muscle and retinal cells was based solely on the infiltration of autologous T cells while graft survival was not assessed. Moreover, since BLT mice are deficient in functional natural killer (NK) cells, presumably due to the absence of human IL-15, the in vivo contribution of the innate immunity, particularly the role of NK cells in the immunogenicity of hiPSC-derived cells was not addressed. To this end, using a combination of humanized mouse models (Hu-BLT and mice reconstituted following the adoptive transfer [AT] of adult peripheral blood mononuclear cells [PBMCs; Hu-AT]), we here provide evidence that skeletal muscle engraftment is not impaired despite autologous immune cell infiltration.

2 | MATERIAL AND METHODS

2.1 | Humanized mice

NOD/SCID/IL2Rγ null (NSG) and NSG-SGM3 (expressing human IL3, GM-CSF, and SCF) mice were obtained from the Jackson Laboratory (Bar Harbor, Maine) and housed in the animal care facility at the CHU Sainte-Justine Research Center under pathogen-free conditions in sterile ventilated racks. All in vivo manipulations were previously approved by the institutional committee for good laboratory practices for animal research (protocol #579). BLT humanized mice (Hu-BLT) were generated by surgical implantation of small pieces (1-2 mm³) of human fetal thymus tissues under the renal capsule and intravenous delivery of CD34⁺ hematopoietic stem cells isolated from autologous fetal liver into 6-week-old NSG mice previously irradiated with 2 Gy total body irradiation (1 Gy/min using a Faxitron CP-160) as previously described. Fetal tissues were obtained from consenting healthy donors after surgical abortion at around week 20 of pregnancy. To monitor the human immune cell engraftment in humanized mice, peripheral blood was collected and leukocytes were purified using a red blood cell lysis solution. Cells were then labeled with conjugated antibodies for human PerCP-Cy5.5-CD45, APC-CD3, PE-CD19, and FITC-CD4 (see Table S1 for a complete list of antibodies used) and analyzed by flow cytometry (BD FACSCANTO II, BD Biosciences). For AT experiments, human adult peripheral blood was collected and immune cells purified by Ficoll (GE healthcare). Mice were injected intravenously with 1 x 10⁷ freshly isolated PBMCs.

2.2 | Generation and characterization of hiPSCs

Fibroblasts were first isolated either from human fetal liver tissues or human skin after collagenase dissociation. Single cell fibroblasts cultures were then reprogrammed into hiPSCs using integration-free Sendai virus (Cytochrome 2.0 kit catalog # A16517 from Life Technologies). Fibroblasts were used at low population doubling (between 5 and 10) to increase efficiency of reprogramming. Emerging colonies from transduced cells were manually picked and cultured under feeder-free conditions in Essential 8 and Essential 2.4 Flex medium on Geltrex-coated dishes (Life Technologies). hiPSC clones were passaged at least 15 times to increase stable pluripotency. hiPSC generation and characterization were done in the iPSC-cell reprogramming core facility of CHU Sainte-Justine. hiPSC colonies were stained with the antibodies for anti-human SSEA-4, Sox2, OCT4, and TRA1-60 overnight at 4°C. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI). Karyotypes were produced by G-banding and analyzed by the CHU Ste-Justine cytogenetic department.

2.3 | Differentiation into myogenic progenitor cells

Myogenic progenitor cells (MPCs) were generated either directly from fibroblasts, or following fibroblast reprogramming into hiPSCs (hiPSC-MPCs). Differentiation of fibroblasts into MPCs was obtained after transduction with a MyoD-expressing adenovirus for 5 hours at MOI 30. hiPSC-MPCs were differentiated by first culturing hiPSC colonies in MB1 myogenic medium (HyClone) supplemented with 10 ng/mL of basic fibroblast growth factor (bFGF) for 5 days on Geltrex-coated culture dishes and then transduced with a MyoD-expressing adenovirus as described above. Both MPCs and hiPSC-MPCs were used the day after transduction to avoid premature fusion of the cells.

2.4 | Splenocyte and T-cell activation assays

Splenocytes and PBMCs were isolated from Hu-BLT mice following mechanical digestion of the spleen or isolation using Ficoll, respectively. Effector cells (splenocytes or PBMCs) were then cocultured with

Significance statement

The immunogenicity of human induced pluripotent stem cell (iPSC)-derived cells will strongly influence their use in regenerative medicine. This important feature has so far been mostly understudied given the necessity to have access to humanized mice reconstituted with an immune system autologous to iPSC-derived cells. Using two distinct humanized mouse models, this study provides evidences that human immune cell infiltration in skeletal muscle should not be used as the sole marker to predict immunogenicity. Indeed, we show that human iPSC-derived myogenic progenitors, similar to primary human myoblasts, are tolerated despite being infiltrated by autologous T cell. This study provides essential preclinical data supporting the usage of human iPSC-derived myogenic progenitor cells.
FIGURE 1  Legend on next page.
either autologous or allogeneic MPCs or myotubes (1 x 10^5 or 2 x 10^5) at 1:2 ratio during 3 days at 37°C. Effector cells were added to MPCs directly after transduction with MyoD or after a 5-day culture in 2% fetal bovine serum to allow the formation of myotubes. T-cell activation was measured with a phycoerythrin (PE)-conjugated anti-human CD45RO or CD3 antibody (BD Biosciences). Effector cells without stimulation were used as a negative control, and phytohemagglutinin (10 μg/mL) or an anti-CD3 (OKT3) antibody were used as positive controls. 7-AAD (catalog # 51.68981E from BD Biosciences) was used to exclude dead cells.

2.5 NK cell degranulation and cytotoxicity assays

NK cells were purified from fresh PBMCs using the NK cell enrichment negative selection kit (catalog #19055 from STEMCELL Technologies) and incubated with or without target cells at the indicated ratios. K562 cells were used as a positive control in all experiments. For the NK cell degranulation assay, effector and target cells (1 x 10^5 or 2 x 10^5) were cocultured at 1:2 ratio in the presence of FITC-conjugated anti-human CD107a/b for 1 hour at 37°C, then 2 μL/mL of monensin (catalog # 554724 from BD Biosciences) was added to the cell mixture for an additional 3 hours of incubation. For cytotoxicity assay, effector and PKH26-stained target cells (1 x 10^5 or 5 x 10^4) were mixed at 1:1 or 5:1 ratio and incubated for 4 hours at 37°C. At the end of the incubation, degranulation was quantified by flow cytometry (BD LSRFortessa, BD Biosciences) after gating on CD3+/CD56+/CD107+ viable cells and the extent of cytotoxicity was determined by the relative number of live target cells labeled with PKH26 and dead cells labeled with both PKH26 (catalog # PKH26GL-1KT from Sigma-Aldrich) and 7-AAD (BD Biosciences).

2.6 Fetal fibroblast and myoblast isolation

Fetal muscle and liver biopsies were minced into small pieces and digested using a solution of phosphatase buffered saline (PBS) with 0.2% of collagenase (Roche) and 0.25% of dispase (STEMCELL Technologies) at 37°C during 30 minutes with manual intermittent mixing. Myoblasts and fibroblasts were then cultured and expanded respectively in myogenic MB1 medium and 10% fetal bovine serum-supplemented Dulbecco's modified Eagle's medium (DMEM). Where indicated, only myoblasts expressing the highest level of CD56 were expanded and transplanted into mice.

2.7 Intramuscular transplantation of myogenic cells

Tibialis anterior (TA) muscle of mice were transplanted with 1 x 10^6 myogenic cells (either myoblasts, MPCs, or hiPSC-MPCs) in 20 μL of PBS containing 10 μg/mL of cardiotoxin (cat# 217503-1MG from Sigma). Of note, cardiotoxin was injected together with cells, rather than 24 hours before cell transplantation, to prevent any premature recruitment of immune cells due to muscle damage. The grafted TA muscles were harvested 4 weeks after transplantation and frozen in optimal cutting temperature compound (OCT, VWR). Cryosections of transplanted muscles were immunostained with anti-human specific dystrophin (Developmental Studies Hybridoma Bank, University of Iowa) and antibodies against human CD4, CD8, and Nkp46/NCR1 (all from Biolegend). For FKS06 treatment, mice were injected intraperitoneally with Tacrolimus (1 mg/kg daily). Control mice were injected with PBS.

2.8 MPC characterization and differentiation in vitro

MPCs cultured in MB1 were fixed and permeabilized using ethanol 95% and immunostained with a mouse anti-human Desmin antibody from DAKO overnight at 4°C and an anti-mouse ALEXA fluor 594 (1:500 from Invitrogen) at room temperature for 1 hour. Confluent MPCs were maintained in DMEM supplemented with 2% fetal bovine serum and antibiotics for 3 to 5 days. Myotubes were then immunostained with a mouse anti-Myogenin (1:500 from Abcam) or a mouse anti-MyHC antibody (1:100 from the Developmental Studies Hybridoma Bank, University of Iowa) and a mouse anti-MyHC antibody (1:100 from the Developmental Studies Hybridoma Bank, University of Iowa) and visualized using a confocal microscope.

**FIGURE 1** Fibroblast-derived myogenic progenitor cells are immune tolerated in Hu-BLT mice. A. Schematic of the BLT humanized mouse model (Hu-BLT). NSG mice were transplanted with human fetal thymus and autologous liver-derived CD34+ cells. At week 10 (W10) postimmune reconstitution, human myogenic progenitor cells (MPCs) derived from fetal liver fibroblasts were transplanted in the Tibialis anterior of Hu-BLT. Mice were sacrificed 4 weeks later, and muscles were harvested and analyzed for cell engraftment and infiltration of immune cells. B. Representative photos of muscle sections from Hu-BLT and NSG mice showing increased engraftment of autologous compared to allogeneic human MPCs and resulting human specific dystrophin-positive fibers (in red). 4',6-Diamidino-2-phenylindole (DAPI) staining was performed to visualize nuclei (in blue). Shown are photos taken at ×20. Scale bar = 100 μm. C. Counts of human dystrophin positive fibers observed in muscle sections of Hu-BLT mice transplanted with MPCs as shown in panel (B). Also showed are counts in nonimmune reconstituted NSG mice to assess overall engraftment potential of the different donors. Each dot represents the mean ± SEM number of dystrophin positive fibers from five selected sections in each muscle. n = 4. D. Representative photos showing CD4 and CD8 T-cell infiltration (in red) in muscle sections of NSG (negative control) and Hu-BLT mice transplanted with autologous or allogeneic MPCs. DAPI staining was performed to visualize nuclei (in blue). Shown are photos taken at ×40. Scale bar = 100 μm. E. Frequency of CD4 and CD8 T cells infiltrated in muscle of Hu-BLT mice as shown in panel (D). Each dot represents the number of T cells in four randomly selected fields in each muscle. n = 4. F. Splenocytes were collected from Hu-BLT mice 10 weeks after immune reconstitution, and the activation of T cells (as determined by gating CD3+/CD69+ cells) was measured after a coculture with autologous or allogeneic MPCs or myotubes (ratio 1:2) for 3 days. PHA was used as a positive control. Shown is the mean ± SEM of two independent experiments done in triplicate using splenocytes collected from two different mice. MPCs, myogenic progenitor cells; PHA, phytohemagglutinin.
University of Iowa) for 2 hours at room temperature and an anti-mouse ALEXA fluor 594 (1:500) at room temperature for 1 hour. Nuclei were counterstained with DAPI. Cells were then phenotypically characterized by flow cytometry (BD LSRFortessa, BD Biosciences) using conjugated antibodies against HLA-I, CD80, CD83, CD86, MICA/B, and CD112/155 (see Table S1 for a complete list of antibodies used).

**FIGURE 2** Legend on next page.
2.9 Statistical analysis

GraphPad Prism 8 software was used for statistical analysis; P values on multiple comparisons were calculated using Student’s t tests. *P < .05, **P < .01, ***P < .001, ****P < .0001.

3 RESULTS

3.1 Infiltration of autologous T cells in skeletal muscle does not mediate immune rejection in Hu-BLT mice

To evaluate the immunogenicity of skeletal muscle cell grafts, we used cells either obtained directly from a fetal muscle biopsy (myoblasts) or MPCs differentiated from fetal liver fibroblasts (Figures 1A and 2A). MPCs were generated using an efficient two-step protocol leading to a high differentiation efficiency (100% of the cells expressing CD56) as we previously described.10 In brief, cells were first differentiated towards a mesenchymal-like phenotype using myogenic media (see Methods) followed by the ectopic expression of MyoD using a nonreplicative type 5 adenoviruses containing the murine MyoD under a recombinant cytomegalovirus early enhancer/chicken β-actin (CAG) promoter.12 We first confirmed that myoblasts and iPSC-MPCs were positive for the myogenic markers CD56, CD82, Desmin and were fully capable of forming myotubes in vitro when placed under differentiation conditions (Figure S1). Immunogenicity was determined after cells were transplanted into the Tibialis anterior of Hu-BLT mice showing high levels of reconstitution with either autologous or allogeneic immune cells (Figures 1A-C and S2). Our results showed that 4 weeks after transplantation, muscle sections had a higher number of human dystrophin-expressing myofibers resulting from the fusion of autologous compared to allogeneic MPCs (Figure 1B,C). As expected, muscles transplanted with allogeneic MPCs were highly infiltrated with CD4 and CD8 T cells (Figure 1D,E). Surprisingly, transplanted autologous muscles were also infiltrated with CD4 and CD8 T cells although at a much lower level (Figure 1E). Importantly, the engraftment of MPCs was not impaired by the infiltration of autologous T cells as an equal number of fibers expressing the human dystrophin were formed when MPCs were transplanted in nonreconstituted immune-deficient NOD/SCID/IL2Rγ null (NSG) mice (Figure 1C). Next, to demonstrate that lower engraftment in an allogenic condition was indeed mediated by immune cells, we transplanted allogeneic myoblasts into muscles of another group of Hu-BLT mice treated or not with the immunosuppressive drug FK506. Mice were treated daily starting from the day of transplantation until the day of sacrifice for a total of 4 weeks. Our results showed that FK506 treatments prevented the rejection of allogeneic myoblasts which is consistent with a T cell-dependent immune rejection mechanism (Figures S3A-C). Moreover, an in vitro mixed lymphocyte reaction (MLR)-like test showed that allogeneic but not autologous MPCs and myotubes were able to activate T cells after a tree day coculture with splenocytes collected from fully reconstituted Hu-BLT mice (Figure 1F).

To determine if the low level infiltration of autologous T cells was specific to the differentiation procedure of MPCs, primary myoblasts isolated directly from a fetal muscle biopsy were transplanted into the Tibialis anterior of Hu-BLT mice generated with thymus and hematopoietic cells obtained from the same donor as the myoblasts (Figure 2A). To our surprise, 4 weeks after cell transplantation, we also found muscles transplanted with autologous primary myoblasts to be infiltrated with CD4 and CD8 T cells at a level similar to what we observed using autologous MPCs (Figures 1D,E and 2D,E). Of note, sham injected muscles also had infiltrating CD4 and CD8 T cells suggesting low level inherent immune infiltration in muscle of Hu-BLT mice. As observed with MPCs, the infiltration of T cells did not compromise engraftment of transplanted myoblasts (Figure 2B,C). Of note, we observed a striking increase in the number of engrafted human muscle fibers in experiment 2 compared to experiment 1, a phenotype unlikely to be explained by the inherent donor to donor variation. Instead, we believe such an increase is likely explained by the fact that MPCs from donor 2 were sorted for the expression of CD56 and that only the cells expressing the
highest level were injected in mice (Figure S1B). Nonetheless, such an increase in engraftment levels did not translate into an increase number of immune cells infiltration (Figure 2E). These results suggest that infiltration of autologous T cells alone should not be considered as a predictive marker of successful engraftment in skeletal muscles.

**FIGURE 3** Legend on next page.
3.2 | hiPSC-MPCs are not the target of autologous T and NK cells in vitro

To better reflect future clinical settings, we then choose to differentiate MPCs from hiPSCs, instead of from fibroblasts and to evaluate their immunogenicity to T and NK cells in both autologous and allogeneic in vitro conditions. We first generated hiPSC clones using the integration-free (Sendai virus) approach and confirmed they had normal karyotypes, expressed the classic markers of pluripotency and were able of forming in vivo teratoma in immune-deficient mice (Figure S4A,B and data not shown), then we generated MPCs using the same two-step differentiation protocol described above (Figure S1A). Using hiPSC-MPCs, we then performed an MLR-like assay using PBMCs and a cytotoxicity assay using PBMC-purified NK cells. Our results show that hiPSC-MPCs and their derived myotubes significantly activated allogeneic but not autologous T cells—even at the highest ratio (1:10) of PBMCs vs hiPSC-MPCs (Figure 3A-C). In addition, none of hiPSC-MPCs or their derived myotubes were able to induce NK cell-degranulation and/or specific cytotoxicity (Figure 3D-G). This could be explained by the fact that hiPSC-MPCs, in opposition to hiPSC, express high levels of HLA-I as we have shown before.13

3.3 | hiPSC-derived myofibers are not rejected in Hu-AT mice

To confirm our results showing the absence of NK-mediated cytotoxicity in vitro and because Hu-BLT mice are deficient in functional NK cells, we choose to further evaluate the immunogenicity of MPCs using a different humanized mouse model that combines functional T and NK cells. To this end, we adoptively transferred 10⁷ human PBMCs obtained from the same donors as the fibroblasts that were used to generate hiPSCs in NSG-SGM3 mice (Figure 4A). We here choose to use NSG-SGM3 mice based on previous work from our laboratory showing that AT of human PBMCs in these mice was highly effective at rejecting both autologous and allogeneic tumor cells.14 Moreover, NSG-SGM3 mice were shown to better support the engraftment of myeloid lineages that could play an important role in the first steps of the immune response.15 Hence, similar to what we observed in Hu-BLT mice, 4 weeks post transplantation more dystrophin-positive myofibers were observed in muscles of mice injected with autologous compared to allogeneic PBMCs (Figure 4B, C). Muscle tissues of both allogeneic and autologous mice were however highly infiltrated with CDB T cells (Figure 4D,E). Yet, the infiltration of autologous CDB T cells had surprisingly no impact on the graft as the number of hiPSC-MPCs-derived myofibers was not higher in non-reconstituted NSG-SGM3 mice (Figure 4C). Infiltration of CDB T cells was likely not specific to grafted human myofibers as non-injected muscle sections were also heavily infiltrated with CDB T cells suggesting mice were at an early stage of a full xenograft reaction (data not shown). Overall, our results demonstrate that hiPSC-derived muscular grafts are likely to be tolerated by autologous T cells, rejected by allogeneic T cells and not the target of NK cells.

4 | DISCUSSION

The success of future hiPSC-derived cell therapies, whether obtained from autologous donors or through the development of universal cell lines, will depend on the ability to evade immune recognition.16-18 Using two distinct humanized mouse models, we here provide evidence that MPCs are tolerated by autologous T cells in both Hu-BLT and Hu-AT models and by NK cells in Hu-AT mice. The fact that MPCs were not rejected by NK cells in Hu-AT mice cannot be explain by an insufficient number of NK cells injected. Indeed, we recently showed the injection of a similar number of NK cells was sufficient to prevent the growth of iPSC-derived teratomas in the same model.13 Moreover, our observation in Hu-BLT mice that MPCs attract autologous CD4 and CDB T cells at a level similar to that of myoblasts derived from a muscle biopsy, yet without compromising engraftment, was surprising. Our hypothesis is that T cells may have been attracted by an altered secretory phenotype acquired during the short in vitro growth expansion period of MPCs and myoblasts. Another possibility is that aberrantly expressed antigens may have attracted and induced tolerance/exhaustion of infiltrating autologous T cells. Unfortunately, the low level of infiltrating T cells did not allow to test this hypothesis. It is also important to keep in mind that the capacity of iPSC-derived...
MPCs to arouse an immune response is dependent on the differentiation protocol used and that other differentiation protocols available for the generation of MPCs from iPSCs will also need to be evaluated for their ability to evade the immune system. It also remains to be determined if the presence of autologous T cells can affect long-term engraftment (more than 4 weeks). Indeed, 4 weeks after the AT

**FIGURE 4** Legend on next page.
of PBMCs, we observed equal infiltration of T cells in both autologous and allogeneic conditions in the Hu-AT model (Figure 4E), suggesting mice were at the early stage of graft-vs-host disease. The use of mice that lack the murine MHC allowing to evade graft-vs-host disease but that retain T cell function upon engraftment will likely help to overcome this issue. Our results also provide the first evidence that hiPSC-derived MPCs, unlike hPSCs, are not the target of NK cells in vivo. Overall, our study provides essential preclinical data supporting the usage of fibroblasts or iPSC-derived MPCs in regenerative medicine.

ACKNOWLEDGMENTS
We are grateful to the flow cytometry and animal facility for providing technical support and to Renée Dicaire for handling clinical samples. This work was supported by a grant from the Canadian Institute of Health Research #MOP-126096 to C.B., E.H., and J.P.T., by a grant from le réseau ThéCell from the Fonds de la recherche du Québec - Santé (FRQS) and the support from la Fondation Charles Bruneau for access to technological platforms. C.B. was supported by a senior scientist award from the FRQS.

CONFLICT OF INTEREST
The authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS
B.B: conception and design, experiment performing, collection and assembly of data, data analysis and interpretation, manuscript writing; C.D.-L., M.-L.G., C.C., Y.L., C.M.: experiment performing; J.V.G.: provision of study material; J.P.T.: provision of study material and expertise; E.H.: conception and design; C.B.: conception and design, data analysis and interpretation, manuscript writing.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author.

ORCID
Christian Beauséjour https://orcid.org/0000-0002-1693-5172

REFERENCES
1. Todorova D, Kim J, Hamzeinejad S, He J, Xu Y. Brief report: immune microenvironnment determines the immunogenicity of induced pluripotent stem cell derivatives. Stem Cells. 2016;34:510-515.
2. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474:212-215.
3. Araki R, Uda M, Hoki Y, et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2013;494:100-104.
4. de Almeida PE, Meyer EH, Kooreman NG, et al. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat Commun. 2014;5:3903.
5. Guha P, Morgan JW, Mostoslavsky G, Rodrigues NP, Boyd AS. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell. 2013;12:407-412.
6. Emborg ME, Liu Y, Xi J, et al. Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain. Cell Rep. 2013;3:646-650.
7. Morizane A, Doi D, Kikuchi T, et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports. 2013;1:283-292.
8. Zhao T, Zhang ZN, Westenskow PD, et al. Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells. Cell Stem Cell. 2015;17:353-359.
9. Carson WE, Giri JG, Lindemann MJ, et al. Interleukin (IL)-15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994;180:1395-1403.
10. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012;12:786-798.
11. Goudenege S, Lebel C, Huot NB, et al. Myoblasts derived from normal hESCs and dystrophic hiPSCs efficiently fuse with existing muscle fibers following transplantation. Mol Ther. 2012;20:2153-2167.
12. Fujiwara M, Imai S, Ikawa Y, et al. Effect of release of cytokines and chemokines from human mesenchymal stem cells on the survival of hiPSC-MPCs in vitro. Stem Cells Dev. 2013;22:1237-1245.
13. Benabdollah B, Désaulniers-Langevin C, Colas C, et al. Natural killer cells prevent the formation of teratomas derived from human induced pluripotent stem cells. Front Immunol. 2019;10:2580.
14. Moquin-Beaudry G, Colas C, Li Y, et al. The tumor-immune response is not compromised by mesenchymal stromal cells in humanized mice. J Immunol. 2019;203:2735-2745.
15. Coughlan AM, Harmon C, Whelan S, et al. Myeloid engraftment in humanized mice: impact of granulocyte-colony stimulating factor treatment and transgenic mouse strain. Stem Cells Dev. 2016;25:530-541.
16. Liang Q, Monetti C, Shutova MV, et al. Linking a cell-division gene and a suicide gene to define and improve cell therapy safety. *Nature*. 2018;563:701-704.

17. Deuse T, Hu X, Gravina A, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. *Nat Biotechnol*. 2019;37:252-258.

18. Han X, Wang M, Duan S, et al. Generation of hypoimmunogenic human pluripotent stem cells. *Proc Natl Acad Sci USA*. 2019;116:10441-10446.

19. Chan SS, Arpke RW, Filareto A, et al. Skeletal muscle stem cells from PSC-derived teratomas have functional regenerative capacity. *Cell Stem Cell*. 2018;23:74-85.

20. van der Wal E, Herrero-Hernandez P, Wan R, et al. Large-scale expansion of human iPSC-derived skeletal muscle cells for disease modeling and cell-based therapeutic strategies. *Stem Cell Reports*. 2018;10:1975-1990.

21. Shelton M, Kocharyan A, Liu J, Skerjanc IS, Stanford WL. Robust generation and expansion of skeletal muscle progenitors and myocytes from human pluripotent stem cells. *Methods*. 2016;101:73-84.

22. Brehm MA, Kenney LL, Wiles MV, et al. Lack of acute xenogeneic graft-versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. *FASEB J*. 2019;33(3):3137-3151.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

---

**How to cite this article:** Benabdallah B, Désaulniers-Langevin C, Goyer M-L, et al. Myogenic progenitor cells derived from human induced pluripotent stem cell are immune-tolerated in humanized mice. *STEM CELLS Transl Med*. 2021;10:267–277. [https://doi.org/10.1002/sctm.19-0452](https://doi.org/10.1002/sctm.19-0452)